SCHEDULE: FMR LLC Reports 9.2% Stake in Eikon Therapeutics

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 9.2% of Eikon Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Eikon Therapeutics Inc. common stock.
• As of June 30, 2026, the aggregate amount beneficially owned is 4,993,906 shares, representing 9.2% of the class.
• FMR LLC holds sole voting power for 4,992,603 shares and sole dispositive power for 4,993,906 shares.
• Abigail P. Johnson has sole dispositive power for 4,993,906 shares.
• The filing is an amendment (Amendment No. 1) to a previous filing.
• FIAM LLC and Fidelity Management Trust Company are identified as entities that beneficially own shares.
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial performance data.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson suggests confidence in Eikon Therapeutics' long-term prospects.
• The filing indicates a substantial holding, which could imply a stable shareholder base.

Negatives

• The filing does not provide any new financial performance data or operational updates for Eikon Therapeutics.
• The information is primarily a reporting of ownership, not an indicator of company performance.

Risks

• Potential for future changes in beneficial ownership by FMR LLC or Abigail P. Johnson could impact share price.
• The concentration of ownership could lead to less liquidity if large blocks are traded.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding Eikon Therapeutics' future performance. It solely reports on beneficial ownership.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates FMR LLC's continued interest in Eikon Therapeutics, a biotechnology company, aligning with broader investment trends in the sector.

Management Changes

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor, which may be viewed positively, but provides no direct operational impact.
• Management: The filing confirms ownership stakes but does not directly impact management's operational decisions.
• Creditors: No direct impact on creditors as the filing concerns equity ownership.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to report any material changes in their beneficial ownership of Eikon Therapeutics' common stock.

Key Dates

Keywords

Eikon Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management